Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies
Open Access
- 18 April 2011
- journal article
- review article
- Published by Wiley in Journal of Pineal Research
- Vol. 51 (3) , 270-277
Abstract
Melatonin is an endogenous indoleamine, produced mainly by the pineal gland. Melatonin has been proven to have chronobiotic, antioxidant, antihypertensive, anxiolytic and sedative properties. There are also experimental and clinical data supporting an analgesic role of melatonin. In experimental studies, melatonin shows potent analgesic effects in a dose‐dependent manner. In clinical studies, melatonin has been shown to have analgesic benefits in patients with chronic pain (fibromyalgia, irritable bowel syndrome, migraine). The physiologic mechanism underlying the analgesic actions of melatonin has not been clarified. The effects may be linked to Gi‐coupled melatonin receptors, to Gi‐coupled opioid μ‐receptors or GABA‐B receptors with unknown downstream changes with a consequential reduction in anxiety and pain. Also, the repeated administration of melatonin improves sleep and thereby may reduce anxiety, which leads to lower levels of pain. In this paper, we review the current evidence regarding the analgesic properties of melatonin in animals and humans with chronic pain.Keywords
This publication has 62 references indexed in Scilit:
- Pineal melatonin acts as a circadian zeitgeber and growth factor in chick astrocytesJournal of Pineal Research, 2009
- Microtubules modulate melatonin receptors involved in phase‐shifting circadian activity rhythms: in vitro and in vivo evidenceJournal of Pineal Research, 2009
- When it comes to opiates, just say NOJournal of Clinical Investigation, 2007
- Melatonin attenuates the development of antinociceptive tolerance to delta-, but not to mu-opioid receptor agonist in miceBehavioural Brain Research, 2007
- Postoperative Ileus-Related Morbidity Profile in Patients Treated with Alvimopan after Bowel ResectionJournal of the American College of Surgeons, 2007
- A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomyAmerican Journal of Obstetrics and Gynecology, 2006
- Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgerySurgical Endoscopy, 2005
- Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrityBritish Journal of Surgery, 2004
- Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Effects of diclofenac sodium on intestinal anastomotic healingDiseases of the Colon & Rectum, 1991